Model 1 :AUC=0.896

S2-a1

Model 1:AUC=0.898

S2-a2

Model 2:AUC=0.881

S2-b1

Model 2:AUC=0.875

Sensitivity

1 − Specificity

S2-b2

Sensitivity

Model 3:AUC=0.819

1 − Specificity

S2-c1

Model 3:AUC =0.822

Sensitivity

1 − Specificity

S2-c2

AUC
Model 1=0.896
Model 2=0.881

S2-d1

S2-d2

AUC
Model 2=0.881
Model 3=0.819

S2-e1

AUC
Model 2=0.875
Model 3=0.822

1 − Specificity

Sensitivity

S2-e2

AUC
Model 1=0.896
Model 3=0.819

Sensitivity

1 – Specificity

S2-f1

AUC
Model 1=0.898
Model 3=0.822

S2-f2

AUC

— Model 1=0.896

— Model 2=0.881

— Model 3=0.819

S2-gl

Figure legends

Figure S2. The raw and smooth combinationROC curve of MEWS, RDW, and Creatine for the prediction of 7-day mortality in TBI patients with and without the bootstrapping method (resample: 500), with an area under the receiver operating characteristic curve

Figure S2-a1 The MEWS+RDW raw ROC curve for the prediction 7-day mortality in TBI patients without bootstrapping method ,with an area under the receiver operating characteristic curve (AUROC) of 0.896.

Figure S2-a2 The MEWS+RDW smooth ROC curve for the prediction 7-day mortality in TBI patients obtained by the bootstrapping method (resample: 500), with an area under the receiver operating characteristic curve (AUROC) of 0.898 (95% CI, 0.88,0.92).

Figure S2-b1 The MEWS+creatine raw ROC curve for the prediction 7-day mortality in TBI patients without bootstrapping method ,with an area under the receiver operating characteristic curve (AUROC) of 0.881.

Figure S2-b2 The MEWS+creatine smooth ROC curve for the prediction 7-day mortality in TBI patients obtained by the bootstrapping method (resample: 500), with an area under the receiver operating characteristic curve (AUROC) of 0.875 (95% CI, 0.85,0.90).

Figure S2-c1 The RDW+creatine raw ROC curve for the prediction 7-day mortality in TBI patients without bootstrapping method ,with an area under the receiver operating characteristic curve (AUROC) of 0.819.

Figure S2-c2 The RDW+creatine smooth ROC curve for the prediction 7-day mortality in TBI patients obtained by the bootstrapping method (resample: 500), with an area under the receiver operating characteristic curve (AUROC) of 0.822 (95% CI, 0.79,0.85).

Figure S2-d1 The comparison of raw ROC curves between MEWS+RDW with MEWS+creatine .

Figure S2-d2 The comparison of smooth ROC curves between MEWS+RDW with MEWS+creatine.

Figure S2-e1 The comparison of raw ROC curves between MEWS+creatine with RDW+creatine .

Figure S2-e2 The comparison of smooth ROC curves between MEWS+creatine with RDW+creatine .

Figure S2-f1 The comparison of raw ROC curves between MEWS+RDW with RDW+creatine.

Figure S2-f2 The comparison of smooth ROC curves between MEWS+RDW with RDW+creatine.

Figure S2-g1 The comparison of raw ROC curves between three Models. (Model1:MEWS+RDW,Model2:MEWS+Creatine, Model 3: RDW+Creatine).